{"id":45444,"date":"2025-10-31T20:32:49","date_gmt":"2025-10-31T12:32:49","guid":{"rendered":"https:\/\/flcube.com\/?p=45444"},"modified":"2025-10-31T20:32:50","modified_gmt":"2025-10-31T12:32:50","slug":"bms-reports-q3-2025-results-2-global-revenue-growth","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45444","title":{"rendered":"BMS Reports Q3 2025 Results: 2% Global Revenue Growth"},"content":{"rendered":"\n<p>US\u2011based <strong>Bristol-Myers Squibb (BMS; <a href=\"https:\/\/www.google.com\/finance\/quote\/BMY:NYSE\">NYSE: BMY<\/a>)<\/strong> delivered its third\u2011quarter 2025 earnings, showing a modest 2% year\u2011on\u2011year lift in global sales to <strong>USD\u202f12.2\u202fbillion<\/strong> on a constant\u2011currency basis. The performance of its flagship <strong>Growth Portfolio<\/strong> was a key catalyst, underlined by standout gains in CAR\u2011T therapy, anemia treatment, and cardiac precision medicine.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-revenue-breakdown\">Revenue Breakdown<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market<\/th><th>Q3\u202f2025 Sales<\/th><th>YoY % Change<\/th><th>Currency\u2011Adjusted<\/th><\/tr><\/thead><tbody><tr><td>United States<\/td><td>USD\u202f8.3\u202fbillion<\/td><td>+1\u202f%<\/td><td><\/td><\/tr><tr><td>International<\/td><td>USD\u202f3.9\u202fbillion<\/td><td>+3\u202f%<\/td><td><\/td><\/tr><tr><td><strong>Total<\/strong><\/td><td><strong>USD\u202f12.2\u202fbillion<\/strong><\/td><td><strong>+2\u202f%<\/strong><\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Global growth driven across both domestic and international arenas.<\/li>\n\n\n\n<li>International sales grew slightly faster at 3\u202f% versus 1\u202f% in the US.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-growth-portfolio-dominates\">Growth Portfolio Dominates<\/h3>\n\n\n\n<p>The <strong>Growth Portfolio<\/strong> brought <strong>17\u202f%<\/strong> growth during the quarter, accounting for <strong>USD\u202f6.9\u202fbillion<\/strong> of total revenue. Key contributors were:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Breyanzi<\/strong> (lisocabtagene maraleucel) \u2013 +58\u202f% to <strong>USD\u202f359\u202fmillion<\/strong><\/li>\n\n\n\n<li><strong>Reblozyl<\/strong> (luspatercept) \u2013 +37\u202f% to <strong>USD\u202f615\u202fmillion<\/strong><\/li>\n\n\n\n<li><strong>Camzyos<\/strong> (mavacamten) \u2013 +88\u202f% to <strong>USD\u202f296\u202fmillion<\/strong><\/li>\n\n\n\n<li><strong>Opdivo<\/strong> (nivolumab) \u2013 +6\u202f% to <strong>USD\u202f2.53\u202fbillion<\/strong><\/li>\n\n\n\n<li><strong>Yervoy<\/strong> (ipilimumab) \u2013 +14\u202f% to <strong>USD\u202f739\u202fmillion<\/strong><\/li>\n<\/ul>\n\n\n\n<p>These product milestones underscored BMS&#8217;s balanced pipeline across immuno\u2011oncology and niche specialties.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-updated-full-year-guidance\">Updated Full\u2011Year Guidance<\/h3>\n\n\n\n<p>Buoyed by the robust Growth Portfolio, BMS has nudged its annual revenue outlook higher:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Forecasted FY2025 Sales<\/strong>: <strong>USD\u202f47.5\u201148.0\u202fbillion<\/strong><\/li>\n\n\n\n<li><strong>Prior Guidance<\/strong>: USD\u202f46.5\u201147.5\u202fbillion<\/li>\n<\/ul>\n\n\n\n<p>The lift reflects confidence in sustained demand for its high\u2011margin products and the company\u2019s strategic product expansion.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-investor-takeaway\">Investor Takeaway<\/h3>\n\n\n\n<p>BMS\u2019s ability to generate consistent growth across both its traditional and emerging therapy segments positions it as a durable player in the biopharma space. Market watchers will continue to monitor the trajectory of the Growth Portfolio, particularly the long\u2011haul performance of Breyanzi and Camzyos, as these products contribute significantly to the company\u2019s revenue acceleration.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/BMY-Q3-2025-Earnings-Press-Release.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of BMY-Q3-2025-Earnings-Press-Release.\"><\/object><a id=\"wp-block-file--media-8a50102a-11b5-4d06-b7be-32eb3834c441\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/BMY-Q3-2025-Earnings-Press-Release.pdf\">BMY-Q3-2025-Earnings-Press-Release<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/BMY-Q3-2025-Earnings-Press-Release.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8a50102a-11b5-4d06-b7be-32eb3834c441\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>US\u2011based Bristol-Myers Squibb (BMS; NYSE: BMY) delivered its third\u2011quarter 2025 earnings, showing a modest 2%&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45446,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[429,428,27,849],"class_list":["post-45444","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-bms","tag-bristol-myers-squibb","tag-finanical-reports","tag-nyse-bmy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BMS Reports Q3 2025 Results: 2% Global Revenue Growth - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US\u2011based Bristol-Myers Squibb (BMS; NYSE: BMY) delivered its third\u2011quarter 2025 earnings, showing a modest 2% year\u2011on\u2011year lift in global sales to USD\u202f12.2\u202fbillion on a constant\u2011currency basis. The performance of its flagship Growth Portfolio was a key catalyst, underlined by standout gains in CAR\u2011T therapy, anemia treatment, and cardiac precision medicine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45444\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BMS Reports Q3 2025 Results: 2% Global Revenue Growth\" \/>\n<meta property=\"og:description\" content=\"US\u2011based Bristol-Myers Squibb (BMS; NYSE: BMY) delivered its third\u2011quarter 2025 earnings, showing a modest 2% year\u2011on\u2011year lift in global sales to USD\u202f12.2\u202fbillion on a constant\u2011currency basis. The performance of its flagship Growth Portfolio was a key catalyst, underlined by standout gains in CAR\u2011T therapy, anemia treatment, and cardiac precision medicine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45444\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-31T12:32:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-31T12:32:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3008-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45444#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45444\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BMS Reports Q3 2025 Results: 2% Global Revenue Growth\",\"datePublished\":\"2025-10-31T12:32:49+00:00\",\"dateModified\":\"2025-10-31T12:32:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45444\"},\"wordCount\":274,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45444#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3008-1.webp\",\"keywords\":[\"BMS\",\"Bristol-Myers Squibb\",\"Finanical Reports\",\"NYSE: BMY\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45444#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45444\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45444\",\"name\":\"BMS Reports Q3 2025 Results: 2% Global Revenue Growth - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45444#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45444#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3008-1.webp\",\"datePublished\":\"2025-10-31T12:32:49+00:00\",\"dateModified\":\"2025-10-31T12:32:50+00:00\",\"description\":\"US\u2011based Bristol-Myers Squibb (BMS; NYSE: BMY) delivered its third\u2011quarter 2025 earnings, showing a modest 2% year\u2011on\u2011year lift in global sales to USD\u202f12.2\u202fbillion on a constant\u2011currency basis. The performance of its flagship Growth Portfolio was a key catalyst, underlined by standout gains in CAR\u2011T therapy, anemia treatment, and cardiac precision medicine.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45444#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45444\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45444#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3008-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3008-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"BMS Reports Q3\u202f2025 Results: 2\u202f% Global Revenue Growth\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45444#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BMS Reports Q3 2025 Results: 2% Global Revenue Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BMS Reports Q3 2025 Results: 2% Global Revenue Growth - Insight, China&#039;s Pharmaceutical Industry","description":"US\u2011based Bristol-Myers Squibb (BMS; NYSE: BMY) delivered its third\u2011quarter 2025 earnings, showing a modest 2% year\u2011on\u2011year lift in global sales to USD\u202f12.2\u202fbillion on a constant\u2011currency basis. The performance of its flagship Growth Portfolio was a key catalyst, underlined by standout gains in CAR\u2011T therapy, anemia treatment, and cardiac precision medicine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45444","og_locale":"en_US","og_type":"article","og_title":"BMS Reports Q3 2025 Results: 2% Global Revenue Growth","og_description":"US\u2011based Bristol-Myers Squibb (BMS; NYSE: BMY) delivered its third\u2011quarter 2025 earnings, showing a modest 2% year\u2011on\u2011year lift in global sales to USD\u202f12.2\u202fbillion on a constant\u2011currency basis. The performance of its flagship Growth Portfolio was a key catalyst, underlined by standout gains in CAR\u2011T therapy, anemia treatment, and cardiac precision medicine.","og_url":"https:\/\/flcube.com\/?p=45444","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-31T12:32:49+00:00","article_modified_time":"2025-10-31T12:32:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3008-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45444#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45444"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BMS Reports Q3 2025 Results: 2% Global Revenue Growth","datePublished":"2025-10-31T12:32:49+00:00","dateModified":"2025-10-31T12:32:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45444"},"wordCount":274,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45444#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3008-1.webp","keywords":["BMS","Bristol-Myers Squibb","Finanical Reports","NYSE: BMY"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45444#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45444","url":"https:\/\/flcube.com\/?p=45444","name":"BMS Reports Q3 2025 Results: 2% Global Revenue Growth - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45444#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45444#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3008-1.webp","datePublished":"2025-10-31T12:32:49+00:00","dateModified":"2025-10-31T12:32:50+00:00","description":"US\u2011based Bristol-Myers Squibb (BMS; NYSE: BMY) delivered its third\u2011quarter 2025 earnings, showing a modest 2% year\u2011on\u2011year lift in global sales to USD\u202f12.2\u202fbillion on a constant\u2011currency basis. The performance of its flagship Growth Portfolio was a key catalyst, underlined by standout gains in CAR\u2011T therapy, anemia treatment, and cardiac precision medicine.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45444#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45444"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45444#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3008-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3008-1.webp","width":1080,"height":608,"caption":"BMS Reports Q3\u202f2025 Results: 2\u202f% Global Revenue Growth"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45444#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BMS Reports Q3 2025 Results: 2% Global Revenue Growth"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3008-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45444"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45444\/revisions"}],"predecessor-version":[{"id":45448,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45444\/revisions\/45448"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45446"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}